Back to Search
Start Over
Stereotactic body radiation therapy for the primary treatment of localized prostate cancer.
- Source :
-
Journal of radiation oncology [J Radiat Oncol] 2013 Mar; Vol. 2 (1), pp. 63-70. Date of Electronic Publication: 2012 Sep 12. - Publication Year :
- 2013
-
Abstract
- Objective: The low alpha/beta ratio of prostate cancer suggests that hypofractionated schemes of dose-escalated radiotherapy should be advantageous. We report our experience using stereotactic body radiation therapy (SBRT) for the primary treatment of prostate cancer to assess efficacy and toxicity.<br />Methods: From 2007 to 2010, 70 patients (51 % low risk, 31 % intermediate risk, and 17 % high risk) with localized prostate cancer were treated with SBRT using the CyberKnife system. One-third of patients received androgen deprivation therapy. Doses of 37.5 Gy ( n = 29), 36.25 Gy ( n = 36), and 35 Gy ( n = 5) were administered in five fractions and analyzed as high dose (37.5 Gy) vs. low dose (36.25 and 35 Gy).<br />Results: At a median 27 and 37 months follow-up, the low and high dose groups' median PSA nadir to date was 0.3 and 0.2 ng/ml, respectively. The 3-year freedom from biochemical failure (FFBF) was 100 %, 95.0 % and 77.1 % for the low-, intermediate- and high-risk patients. A dose response was observed in intermediate- and high-risk patients with 72 % vs. 100 % 3-year FFBF for the low and high dose groups, respectively ( p = 0.0363). Grade III genitourinary toxicities included 4 % acute and 3 % late (all high dose). Potency was preserved in 83 % of hormone naïve patients.<br />Conclusion: CyberKnife dose escalated SBRT for low-, intermediate- and high-risk prostate cancer exhibits favorable efficacy with acceptable toxicity.
Details
- Language :
- English
- ISSN :
- 1948-7894
- Volume :
- 2
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of radiation oncology
- Publication Type :
- Academic Journal
- Accession number :
- 23504305
- Full Text :
- https://doi.org/10.1007/s13566-012-0067-2